Giuseppe Banna, Consultant Medical Oncologist at Portsmouth Hospitals University NHS Trust, shared a post on LinkedIn:
“I truly enjoyed being part of this insightful symposium with Verane Achard, Teresa Lopez, and Alberto Briganti at EAU25, discussing relugolix, an LHRH antagonist with lower cardiovascular risk and rapid, profound castration and PSA decline.
It makes a valuable option in metastatic hormone-sensitive prostate cancer (mHSPC), particularly in the context of treatment de-escalation strategies. – Giuseppe Banna
Great discussions and perspectives – looking forward to continuing the conversation!”
